Biocryst Pharmaceuticals (BCRX) EBIT (QoQ) (2010 - 2026)
Powered by 
Analysis
Biocryst Pharmaceuticals (BCRX) EBIT (QoQ) (2010 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 211.56 Bn | 197.57 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 181.34 Bn | 178.16 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 132.22 Bn | 124.37 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 82.87 Bn | 74.88 Bn | 3.93 Bn |
| 5 | Argenx Se | 61.55 Bn | 56.37 Bn | 1.37 Bn |
| 6 | Moderna | 54.32 Bn | 49.19 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.32 Bn | 31.01 Bn | 992.69 Mn |
| 8 | Biogen | 31.24 Bn | 29.95 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 30.17 Bn | 30.17 Bn | 1.16 Mn |
| 10 | Biocryst Pharmaceuticals | 2.31 Bn | 1.95 Bn | 214.41 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 114.03% |
| Mar 31, 2026 | -369.45% |
| Dec 31, 2025 | 779.95% |
| Sep 30, 2025 | -0.65% |
| Jun 30, 2025 | 40.32% |
| Mar 31, 2025 | 570.87% |
| Dec 31, 2024 | -158.61% |
| Sep 30, 2024 | -12.20% |
| Jun 30, 2024 | 160.47% |
| Mar 31, 2024 | 66.05% |
| Dec 31, 2023 | -257.94% |
| Sep 30, 2023 | 42.42% |
| Jun 30, 2023 | 27.14% |
| Mar 31, 2023 | 38.64% |
| Dec 31, 2022 | -165.47% |
| Sep 30, 2022 | 49.76% |
| Jun 30, 2022 | 30.50% |
| Mar 31, 2022 | 4.25% |
| Dec 31, 2021 | -17.03% |
| Sep 30, 2021 | -50.71% |